NO₂ levels have fallen sharply in northern Italy and China

The novel virus is one of the easiest virus types to deactivate, though SARS-CoV-2-specific data are lacking

Many are FDA-approved drugs that could be repurposed

Italian workers threaten to strike, but German, UK companies and workers pull together

Old anti-malarial drugs have shown mixed results in the small clinical trials conducted so far

The nucleoside inhibitor has advantages over Gilead's remdesivir but has yet to be tested in humans

Qiagen vows to ramp up production of kits as scientists turn to social media to plea for donations

Gilead Sciences' antiviral is in multiple late-stage trials to treat coronavirus infections. Don't expect a home run, say infectious disease experts

Lingering logistic problems and a sputtering economy mean hard times for companies

With a diagnostic backlog hampering disease control efforts, scientists are turning to CRISPR and other technologies to bridge the gap

Drugmakers want to keep trials going but acknowledge that medical resources are strained

Lingering logistic problems and a sputtering economy mean hard times for companies

Editors in Europe and the US plan to work with authors whose lives and labs have been disrupted by the novel coronavirus

Fingers are being pointed in the Netherlands and the UK over reagent capacity constraints

Open-access collection contains nearly 50,000 chemical compounds from the CAS Registry

The chemist wants the Gates Foundation–backed institute to share its expertise during the coronavirus pandemic and advocate for public health

Regulators are restricting reusable bags over worries they might harbor virus

Treatment for rare blood cancers could temper cytokine storm in people with severe forms of the disease

Structural data on the complex could guide drug and vaccine design

Regulators are restricting reusable bags over worries they might harbor virus

Treatment for rare blood cancers could temper cytokine storm in people with severe forms of the disease

Japanese government plans to buy at least 2 million tablets of the influenza drug

Some patients experience neurological, cardiovascular, and intestinal symptoms after infection with SARS-CoV-2

Early earnings figures from chemical makers are down

Tests of 10 or more novel vaccines could be underway by mid-May

Japanese government plans to buy at least 2 million courses of the influenza drug

COVID-19 is driving a fivefold or greater increase in demand

National labs, universities, and companies around the world are fast-tracking proposals to use their high-performance computer resources against the novel coronavirus

Dennis Peters of Indiana University dies from complications of COVID-19

Multiple government agencies and pharma companies join the effort to develop therapeutics and vaccines

Multiple government agencies and pharma companies join the effort to develop therapeutics and vaccines

The novel coronavirus is challenging genome sequencing technology and data processing like never before

ACS volunteer was passionate about mentoring students and helping chemists find jobs

The antimalaria drug will be tested for treating or preventing the disease in thousands of people worldwide

The chemist and former university administrator uses editorials to speak up for science during an ‘extraordinary' time

ACS local sections and members are gathering lab equipment, making chemistry-themed face masks, and more to pitch in during the pandemic

The coronavirus pandemic may mark a rebalancing of where drugs are made as nations recognize a security imperative

Despite the hype, support for the use of chloroquine and its relative hydroxychloroquine outside a clinical trial remains mixed

Limited results from a NIAID study suggest the drug helps people with COVID-19 recover faster